Format

Send to

Choose Destination
J Clin Microbiol. 2015 Jul;53(7):2072-8. doi: 10.1128/JCM.00157-15. Epub 2015 Apr 15.

Improved Standardization of the Bio-Rad Platelia Aspergillus Galactomannan Antigen Sandwich Enzyme Immunoassay Using the DS2 (Dynex) Enzyme-Linked Immunosorbent Assay (ELISA) Processing System.

Author information

1
UK Clinical Mycology Network (UKCMN) Regional Laboratory, Department of Microbiology, Royal Free Hospital, Hampstead, London, United Kingdom rebecca.gorton@nhs.net.
2
UKCMN Regional Laboratory, Public Health Wales, Microbiology Cardiff, UHW, Cardiff, United Kingdom.
3
Population, Policy & Practice Program, UCL Institute of Child Health, London, United Kingdom.
4
UK Clinical Mycology Network (UKCMN) Regional Laboratory, Department of Microbiology, Royal Free Hospital, Hampstead, London, United Kingdom.
5
Centre for Clinical Microbiology, UCL, Royal Free Campus, London, United Kingdom.

Abstract

The galactomannan enzyme immunoassay (GM-EIA) is widely utilized for the diagnosis of invasive aspergillosis (IA). There is inconsistent reproducibility of results between centers when the assay is processed manually. Automation of EIAs can reduce variation. This study investigated the semiautomation of the GM-EIA on the DS2 (Dynex) platform in the following three stages: (i) DS2 GM-EIA method validation with experimental samples, (ii) DS2 retesting of case-defined clinical samples, and (iii) a 12-month audit of DS2 GM-EIA performance. In stage i, Bland-Altman analysis demonstrated a reduced variance between optical density index (ODI) values for samples processed on two DS2 platforms (mean difference, -0.02; limits of agreement [LOA], -0.19 to 0.14) compared with the variance between samples processed manually and on a DS2 platform (mean difference, 0.02; LOA, -0.25 to 0.3). In stage ii, 100% (14/14 samples) qualitative agreement was observed for serum samples from patients with IA, with no significant change in the ODI values when samples were processed on the DS2 platform. A significant decrease in ODI values was observed for control serum samples on the DS2 platform (difference, 0.01; P = 0.042). In stage iii, a significant reduction in the frequency of equivocal results, from 5.56% (136/2,443 samples) to 1.56% (15/961 samples), was observed after DS2 automation (difference, 4.0%; 95% confidence interval [CI], 2.7 to 5.2%; P < 0.01), with an equivalent increase in negative results. This study demonstrates that GM-EIA automation may reduce intersite variability. Automation does not have an impact on the repeatability of truly positive results but contributes to a reduction in false-positive (equivocal) GM-EIA results, reducing the need to retest a significant proportion of samples.

PMID:
25878352
PMCID:
PMC4473217
DOI:
10.1128/JCM.00157-15
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center